METHOD FOR PREDICTION OF RESPONSE TO ANTICANCER THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA Russian patent published in 2024 - IPC G01N33/50 A61B5/00 G01N33/48 

FIELD: biotechnology.

SUBSTANCE: described is a method for prediction of response to anticancer therapy in chronic lymphocytic leukaemia. Method involves multicolour flow cytofluorimetry of expression levels of PD-1 and LAG-3 on a tumour population of B-lymphocytes, LAG-3 on a population of T-lymphocytes, PD-1 on the T-helper population of lymphocytes, PD-1 on the T-cytotoxic population of lymphocytes at the outpatient stage with subsequent substitution of values in two formulas: 1) F1=0.77*X1+0.34*X2+7.76*X3+0.25*X4+0.17*X5-16.86, 2) F2=2.05*X1+0.90*X2+2.11*X3-0.006*X4+0.38*X5-89.69, where X1 is the level of PD-1 expression on the tumour population of B-lymphocytes, X2 is the level of LAG3 expression on the tumour population of B-lymphocytes, X3 is the level of LAG3 expression on the population of T-lymphocytes, X4 is the level of PD-1 expression on the T-helper population of lymphocytes, X5 is PD-1 expression level on T-cytotoxic population of lymphocytes, if F1 is more than F2, a good response to therapy is predicted with a range of values of residual clonal malignant cells-MRD from 0 to 0.9%, if F2 is more than F1, an unsatisfactory response to therapy with MRD is greater than or equal to 1%.

EFFECT: invention extends the range of methods for predicting the response to the anticancer therapy in chronic lymphocytic leukaemia.

1 cl, 2 ex